<DOC>
	<DOC>NCT02762448</DOC>
	<brief_summary>Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent non-Hodgkin Lymphomas Patients Using Daclatasvir and Asunaprevir: A Pilot Study</brief_summary>
	<brief_title>Interferon-free Antiviral Treatment of HCV-Positive Genotype 1b Related Indolent Non-Hodgkin Lymphomas</brief_title>
	<detailed_description>Prospectively collect cases with NHL (n=10), having HCV genotype 1b related NHL, who will be treated with ASV (200 mg twice daily) + DCV(60 mg once daily) for 24 weeks The patients will be observed and followed to determine whether there is regression of NHL after antiviral treatment. Conventional chemotherapy should be initiated shortly in cases without regression.</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>1. Men and women 2. 18 to 70 years of age 3. Who had chronic HCV genotype 1b infection 4. An HCV RNA level of 105 IU per milliliter or higher 5. Being diagnosed to be low grade B cell nonHodgkin lymphoma 1. Patients with hepatitis B virus infection, 2. Other liver diseases 3. HIV infection, 4. Preexisting HCV variants in the NS5A domain included Q30R, L31 M/V, and Y93C/N 5. Evidence of cirrhosis, as documented by means of either liver biopsy or assessment of imaging results.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>